Go to the Globe and Mail homepage

Jump to main navigationJump to main content


QLT profit gets boost from cancer drug sales Add to ...

Drug-maker QLT Inc. says sales of its prostate cancer drug Eligard will grow faster than originally expected this year and already helped boost revenues and profit in the second quarter. The higher sales may also increase the company's chance of selling Eligard, which QLT put on the block many months agoGlobal sales of Eligard rose 12 per cent to $67.6-million (U.S.) in the April-June period compared to last year. QLT-T (TSX) rose 17 cents to $3.57.

Report Typo/Error

Follow us on Twitter: @GlobeBusiness


Next story




Most popular videos »

More from The Globe and Mail

Most popular